Shlomo Shalev - XTL Biopharmaceutica CEO Director

XTLB Stock  ILS 5.90  0.10  1.72%   

Insider

Shlomo Shalev is CEO Director of XTL Biopharmaceuticals
Age 61
Phone972 3 611 6600
Webhttps://www.xtlbio.com

XTL Biopharmaceutica Management Efficiency

The company has return on total asset (ROA) of (0.1001) % which means that it has lost $0.1001 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3822 %, meaning that it generated $0.3822 on every $100 dollars invested by stockholders. XTL Biopharmaceutica's management efficiency ratios could be used to measure how well XTL Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

Jael MScBioLine RX
N/A
Advocate KotlerBioLine RX
71
Omri BatzirIntercure
N/A
Vered RazAvayoForesight Autonomous Holdings
49
David LempertForesight Autonomous Holdings
33
Abi MDBioLine RX
47
Rami LevyIntercure
58
Kfir ZilbermanForesight Autonomous Holdings
42
Sivan ScherfForesight Autonomous Holdings
36
Oren BaronForesight Autonomous Holdings
51
Levy ZruyaForesight Autonomous Holdings
73
Advocate OhayonIntercure
34
Ronen KantorXTL Biopharmaceuticals Ltd
N/A
John LaceyBioLine RX
N/A
OriMoni MimonIntercure
35
Vered KivityBonus Biogroup
N/A
Itay WeinsteinXTL Biopharmaceuticals Ltd
53
Doron CohadierForesight Autonomous Holdings
44
Raziel FriedBioLine RX
N/A
LLB BScBioLine RX
N/A
Sivan ScherForesight Autonomous Holdings
32
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. XTL BIOPHARMACEUTI is traded on Tel Aviv Stock Exchange in Israel. XTL Biopharmaceuticals (XTLB) is traded on Tel Aviv Stock Exchange in Israel and employs 3 people.

Management Performance

XTL Biopharmaceuticals Management Team

Elected by the shareholders, the XTL Biopharmaceutica's board of directors comprises two types of representatives: XTL Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XTL. The board's role is to monitor XTL Biopharmaceutica's management team and ensure that shareholders' interests are well served. XTL Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XTL Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
Itay Weinstein, Chief Officer
Shlomo Shalev, CEO Director
Ronen Kantor, Company Sec

XTL Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XTL Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in XTL Stock

XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.